Sargent Investment Group LLC Trims Stock Position in Pfizer Inc. (NYSE:PFE)

Sargent Investment Group LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 13.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,557 shares of the biopharmaceutical company’s stock after selling 1,150 shares during the period. Sargent Investment Group LLC’s holdings in Pfizer were worth $219,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Olistico Wealth LLC purchased a new stake in shares of Pfizer in the 2nd quarter valued at approximately $25,000. MFA Wealth Advisors LLC purchased a new stake in Pfizer in the second quarter valued at approximately $29,000. Quarry LP acquired a new position in Pfizer during the second quarter worth $31,000. Financial Connections Group Inc. purchased a new position in shares of Pfizer during the second quarter worth $34,000. Finally, ESL Trust Services LLC acquired a new stake in shares of Pfizer in the first quarter valued at $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Buying and Selling

In other news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of a number of research reports. Barclays lifted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. StockNews.com raised Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Wells Fargo & Company upped their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, Citigroup began coverage on Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective for the company. Eight research analysts have rated the stock with a hold rating, five have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Stock Performance

NYSE PFE opened at $26.02 on Friday. The stock has a market capitalization of $147.46 billion, a price-to-earnings ratio of 35.16, a PEG ratio of 0.85 and a beta of 0.67. The business’s 50 day moving average is $28.76 and its two-hundred day moving average is $28.67. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period in the prior year, the company posted ($0.17) EPS. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.46%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is currently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.